U.S. Biotech Stock News

NasdaqGS:WTW
NasdaqGS:WTWInsurance

Assessing Willis Towers Watson’s Valuation After Stock Pullback Mixed Earnings And RiskAgility FM Upgrade

Willis Towers Watson (WTW) has moved into focus after a sharp pullback from its late 2025 share price peak, mixed quarterly earnings, sector jitters around AI distribution, and a fresh upgrade to its RiskAgility FM platform. See our latest analysis for Willis Towers Watson. Recent volatility has been sharp, with a 7 day share price return of 13.55% and a 30 day share price return of 13.57% pulling Willis Towers Watson back to US$282.98, even though the 3 year total shareholder return of...
NasdaqGM:PTGX
NasdaqGM:PTGXBiotechs

Protagonist Therapeutics (PTGX) Valuation Check After Strong Multi Year Shareholder Returns

Protagonist Therapeutics (PTGX) is back on investor watchlists after recent trading moves, with its latest close at US$81.93 highlighting how the market is currently pricing its late stage pipeline and revenue profile. See our latest analysis for Protagonist Therapeutics. Recent trading has been choppy, with a 1.9% single day share price decline and a modest 7 day share price gain. However, the 1 year total shareholder return of 111.8% and the very large 3 year total shareholder return of...
NYSE:TRN
NYSE:TRNMachinery

A Look At Trinity Industries (TRN) Valuation After Its Recent Share Price Surge

Recent performance and business snapshot Trinity Industries (TRN) has caught investor attention after a recent share price move, with the stock showing strong gains over the past month and past 3 months. This has prompted a closer look at the railcar specialist. The company reports annual revenue of US$2,175.1 million and net income of US$103.3 million, reflecting its role in providing railcar products and services across North America through leasing, maintenance, and manufacturing...
NYSE:CAH
NYSE:CAHHealthcare

Cardinal Health (CAH) Is Down 5.3% After Raising Profit Outlook On Specialty Strength And Capital Returns – Has The Bull Case Changed?

In early February 2026, Cardinal Health reported past second-quarter 2025 results showing sales of US$65,627 million and net income of US$467 million, alongside higher earnings per share and confirmation of its ongoing capital return program through share repurchases and a quarterly dividend of US$0.5107 per share. The company’s stronger pharmaceutical and specialty segment performance, coupled with raised profit guidance and continued investment in higher-margin specialty and services...
NYSE:ADC
NYSE:ADCRetail REITs

Is Agree Realty (ADC) Pricing Look Attractive After Recent 1-Year Share Price Gain?

If you are looking at Agree Realty and wondering whether the current share price reflects its true worth, you are not alone. The stock last closed at US$76.58, with returns of 0.6% over 7 days, 7.2% over 30 days, 6.2% year to date and 11.2% over 1 year, while the 5 year return stands at 47.5%. Recent attention on Agree Realty has focused on its position in the listed real estate sector and on how investors are treating income focused names relative to other asset classes. This context helps...
NasdaqGS:PANW
NasdaqGS:PANWSoftware

Evaluating Palo Alto Networks (PANW) After Recent Share Price Weakness

If you are wondering whether Palo Alto Networks is priced attractively or not, this article walks through the key numbers behind the stock rather than just the headlines. The share price recently closed at US$162.81, with returns of 2.2% over 7 days, a 14.7% decline over 30 days, a 9.2% decline year to date, an 18.6% decline over 1 year, but gains of 92.4% over 3 years and 146.1% over 5 years. Recent news around Palo Alto Networks has focused on its role as a major cyber security provider...
NasdaqGM:CRML
NasdaqGM:CRMLMetals and Mining

Critical Metals Tanbreez Assays Highlight Resource Scale But Share Volatility

Critical Metals (NasdaqGM:CRML) reported final assay results from its 2025 drilling program at the Tanbreez Rare Earths Project in Greenland. The results highlight substantial rare earth mineralization across the project area. Management indicated that the assays reinforce the large scale resource potential and support future development plans. The company plans to use these data to guide further drilling and advance key project milestones in 2026. Critical Metals, trading at $9.83, has...
NYSE:WST
NYSE:WSTLife Sciences

West Pharmaceutical Services Margins Slip To 16.3% Raising Questions Around Bullish Growth Narratives

West Pharmaceutical Services (WST) just posted its FY 2025 third quarter scorecard, with revenue of US$804.6 million and basic EPS of US$1.94 setting the tone for the latest update. The company has seen revenue move from US$702.1 million in Q2 2024 to US$804.6 million in Q3 2025, while basic EPS has ranged from US$1.52 in Q2 2024 to US$1.94 in the latest quarter. This gives investors a clearer view of how the top line and per share earnings have tracked through the last six reported periods...
NYSE:ADM
NYSE:ADMFood

Akralos Venture Puts ADM Animal Nutrition And Valuation In Focus

ADM (NYSE:ADM) and Alltech have launched Akralos, a North American animal nutrition joint venture, which is now fully operational. The venture combines ADM’s feed operations with Alltech’s brands and expertise in animal nutrition. Akralos is positioned as one of the largest animal feed and nutrition platforms in North America. For you as an investor looking at ADM (NYSE:ADM), Akralos ties directly into the company’s existing footprint in agricultural processing and animal feed. Animal...
NYSE:TRU
NYSE:TRUProfessional Services

TransUnion (TRU) Margin Jump To 9.5% Challenges Earnings Skeptics

TransUnion (TRU) just posted its latest FY 2025 numbers with Q3 revenue of US$1.2b, basic EPS of US$0.50 and net income excluding extra items of US$96.6m, set against trailing 12 month revenue of US$4.4b and EPS of US$2.16. These figures reflect an 87.5% year over year earnings jump and a move in net margin from 5.5% to 9.5%. The company has seen quarterly revenue range from US$1.0b in Q4 2024 to US$1.2b in Q3 2025. Over the same period, quarterly EPS moved from US$0.34 to US$0.76 and then...
NYSE:BMI
NYSE:BMIElectronic

Is Badger Meter’s (BMI) Insider Buying Amid Margin Pressures Quietly Reframing Its Competitive Narrative?

In early February 2026, Badger Meter reported a fourth-quarter earnings miss while Executive Vice President Robert Wrocklage acquired 1,650 company shares amid ongoing cost and competitive pressures. This combination of weaker-than-expected results, margin headwinds and insider buying has sharpened investor focus on the company’s resilience and long-term positioning in smart water infrastructure. With insider buying occurring alongside margin pressures from tariffs and input costs, we’ll now...
NasdaqGS:LRCX
NasdaqGS:LRCXSemiconductor

Assessing Lam Research (LRCX) Valuation After Earnings Beat And New AI Collaboration With CEA Leti

Lam Research (LRCX) is back in focus after reporting quarterly results ahead of analyst expectations and unveiling a multi year collaboration with CEA Leti, aimed at next generation semiconductor devices for AI and high performance computing. See our latest analysis for Lam Research. The recent earnings beat and CEA Leti partnership come on top of strong price momentum, with a 90 day share price return of 56% and a very large 1 year total shareholder return of 180.2%. This suggests investors...
NYSE:MTN
NYSE:MTNHospitality

Assessing Vail Resorts (MTN) Valuation After Recent Share Price Weakness

What Vail Resorts Stock’s Recent Performance Signals With no single headline event setting the tone, Vail Resorts (MTN) has drawn attention as investors weigh its recent share performance and current fundamentals against its established position in mountain resorts and destination travel. See our latest analysis for Vail Resorts. At a share price of US$136.93, Vail Resorts has seen short term share price pressure, with a 30 day share price return of 3.30% decline and a 12 month total...
NasdaqGS:AGIO
NasdaqGS:AGIOBiotechs

Agios Pharmaceuticals Q3 Loss Of US$103.4m Reinforces Bearish Profitability Narratives

Agios Pharmaceuticals (AGIO) just posted its FY 2025 third quarter numbers, with revenue of US$12.9 million, basic EPS of a US$1.78 loss, and a net income loss of US$103.4 million. The trailing twelve month figures show revenue of US$44.8 million and a net loss of US$401.3 million. The company’s quarterly revenue moved from US$8.6 million in Q2 2024 to US$12.9 million in Q3 2025, while basic EPS shifted from US$16.65 in Q3 2024, driven by a one-off gain, to consistent losses across recent...
NYSE:PGR
NYSE:PGRInsurance

How Analyst Upgrades And Brandes’ Bigger Bet At Progressive (PGR) Have Changed Its Investment Story

In recent days, Progressive has drawn attention as multiple Wall Street firms reiterated positive views following strong December and quarterly results, while a major institutional investor, Brandes Investment Partners, increased its stake in the insurer. This combination of upbeat analyst commentary, institutional buying, and robust industry profitability amid rising auto premiums highlights renewed confidence in Progressive’s data-driven business model. We’ll now examine how this show of...
NYSE:BW
NYSE:BWElectrical

Does Babcock & Wilcox Enterprises' (BW) UK-Sweden Frigate Link Hint At A Deeper Defense Role?

Babcock and Saab have announced that they have jointly developed the Arrowhead-120 frigate design for Sweden’s Luleå-class programme, proposing a split-build model with hulls constructed in Scotland and composite superstructures plus combat system integration completed in Sweden from around 2030. This collaboration underscores Sweden’s emphasis on local industrial participation and sovereign control while deepening UK-Sweden defence ties and enhancing NATO interoperability in Northern...
NYSE:NSP
NYSE:NSPProfessional Services

A Look At Insperity (NSP) Valuation After Recent Share Price Weakness

What recent performance says about Insperity stock Insperity (NSP) has been under pressure recently, with the share price showing negative returns over the past week, month, past 3 months, year to date, and past year, setting a cautious backdrop for investors. See our latest analysis for Insperity. The latest 1 day share price return of a 13.6% decline, combined with a 42.1% decline over 30 days and a 68.6% decline in 1 year total shareholder return, points to fading momentum as investors...
NYSE:GXO
NYSE:GXOLogistics

GXO Logistics (GXO) Is Up 14.1% After Mixed 2025 Results And New Defense Wins Has The Bull Case Changed?

In February 2026, GXO Logistics reported fourth-quarter 2025 revenue of US$3,507 million and full-year revenue of US$13.18 billion, alongside a sharp fall in net income to US$43 million for the quarter and US$32 million for the year, and issued 2026 guidance for 4%–5% organic revenue growth. At the same time, GXO deepened its push into aerospace, defense, and automotive logistics through new BMW Group and BAE Systems contracts and the creation of a Defense Advisory Board, while also winning...
NYSE:BOX
NYSE:BOXSoftware

Assessing Box (BOX) Valuation After Prolonged Share Price Weakness

Box stock snapshot after recent share performance Box (BOX) has recently seen weaker share performance, with the stock showing a 2.3% decline over the past day, 6.2% over the past week, and deeper pullbacks over the month and past 3 months. See our latest analysis for Box. With the share price now at $22.80, a year-to-date share price return of a 20.92% decline, and a 1-year total shareholder return of a 35.58% decline, recent weakness suggests momentum has been fading rather than building...
NYSE:MO
NYSE:MOTobacco

Is It Time To Reassess Altria Group (MO) After Its Strong Multi‑Year Share Price Run?

If you are wondering whether Altria Group's current share price reflects its true worth, the starting point is to look closely at how the market is pricing its cash flows and risk today. The stock last closed at US$67.01, with returns of 2.5% over 7 days, 11.4% over 30 days, 16.9% year to date, 33.9% over 1 year, 79.5% over 3 years and 126.7% over 5 years. This naturally raises questions about how much of the story is already in the price. Recent headlines around Altria Group have focused on...
NasdaqGS:COLM
NasdaqGS:COLMLuxury

Is Columbia Sportswear (COLM) Fairly Priced After Recent Rebound In Share Price?

If you are wondering whether Columbia Sportswear is attractively priced or just a value trap, looking closely at its current valuation is a useful next step. The stock last closed at US$61.88, with returns of 1.3% over 7 days and 11.8% over 30 days, although the 1 year return of negative 23.6% and 5 year return of negative 35.1% show a very different picture. Recent attention on Columbia Sportswear has been shaped by ongoing discussions around brand strength, inventory trends and consumer...
NYSE:TKO
NYSE:TKOEntertainment

Does Insider Selling Amid Media Rights Optimism Reveal a Deeper Shift in TKO (TKO)’s Story?

In early February 2026, an SEC filing showed that Shane Kapral, a deputy CFO at a TKO Group Holdings subsidiary, sold 616 company shares, while recent fund commentary highlighted TKO’s role as the owner of UFC and WWE and its exposure to growing sports media demand. Cooper Investors’ emphasis on TKO’s media rights renewals and expanding multi-year sponsorship deals underscores how its combat sports assets are being leveraged across broadcast and commercial partnerships. We’ll now explore how...
NasdaqGS:FLNC
NasdaqGS:FLNCElectrical

Fluence Energy Faces Margin Strain Yet Builds Record Storage Backlog

Fluence Energy (NasdaqGS:FLNC) reported mixed quarterly results, with project cost overruns weighing on margins. The company recorded more than $750 million in new orders in the quarter, leading to a record backlog for its energy storage solutions. Revenue grew year over year, despite operational challenges tied to higher project costs. Fluence Energy, which last closed at $17.44, has had a volatile share price lately, with a 7 day return of an 8.0% decline and a 30 day return of a 26.8%...
NYSE:SNAP
NYSE:SNAPInteractive Media and Services

Assessing Snap’s Valuation After Earnings Beat Gucci AI Partnership And Legal Scrutiny

Snap (SNAP) just wrapped up a busy stretch, beating Wall Street’s fourth quarter expectations, closing a US$500 million buyback, rolling out new products and facing fresh legal scrutiny in Texas. See our latest analysis for Snap. Despite the recent earnings beat and completion of the US$500 million buyback, investor sentiment has been weak. Snap’s 30 day share price return of 39.67% and 1 year total shareholder return of 57.16% both point to fading momentum. Recent headlines, from the Gucci...